HENGRUI PHARMA - [Overseas Regulatory Announcement - Other] — 2026082601180
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
（於中華人民共和國註冊成立的股份有限公司）
（股份代號：1276）
海外監管公告
本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。
根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。
承董事會命
江蘇恒瑞醫藥股份有限公司
董事長
孫飄揚先生
中國上海
2026年8月26日
於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii)獨立非執行董事樓麗廣先生、曾慶生先生、孫金雲先生及周紀恩先生。
证券代码：600276证券简称：恒瑞医药公告编号：临2026-130
江苏恒瑞医药股份有限公司
关于以集中竞价交易方式回购公司股股份的
A
回购报告书
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。
重要内容提示：
● 回购股份金额：本次回购的江苏恒瑞医药股份有限公司（以下简称"公司"或"本公司"）A股股份（以下简称"A股股份"）（以下简称"回购"或"回购方案"）使用资金总额为不低于人民币10亿元，不超过人民币20亿元；
● 回购股份资金来源：公司自有资金；
● 回购股份用途：本次回购的股份拟用于A股员工持股计划；
● 回购股份价格：回购价格不超过人民币81.78元/股；
● 回购股份方式：采用集中竞价交易的方式从二级市场回购A股股份；
● 回购股份期限：自公司董事会（以下简称"董事会"）审议通过回购方案之日起不超过12个月（以下简称"回购期限"）；
● 相关股东是否存在减持计划：
根据公司对控股股东、实际控制人、董事、高级管理人员、持股 5%以上的股东的问询及其回复，截至董事会审议通过本次回购方案之日，公司控股股东、实际控制人、董事、高级管理人员、持股 5%以上的股东在未来 3 个月、未来 6 个月暂无减持公司股份计划。如上述主体未来拟实施减持股份计划，公司将按照法律法规及规范性文件要求及时履行信息披露义务。
● 相关风险提示：
1、若本次回购期限内，公司股票价格持续超出回购方案披露的价格区间，可能存在本次回购方案无法实施的风险；
2、公司在实施回购方案期间，受宏观经济调控、临时经营需要等因素影响，致使回购股份所需资金未能及时到位，导致回购方案无法按计划实施的风险；3、因公司生产经营、财务状况、外部客观情况发生重大变化等原因，可能存在根据相关规定变更或终止回购方案的风险；
4、本次回购的股份用于公司A股员工持股计划，可能存在因A股员工持股计划无法实施等原因，导致已回购股票无法授出或转让的风险。
公司将在回购期限内根据市场情况择机做出回购决策并予以实施，并根据回购股份事项进展情况及时履行信息披露义务，敬请广大投资者注意投资风险。
一、回购方案的审议及实施程序
2026年8月19日，公司召开第十届董事会第四次会议，审议通过《关于以集中竞价交易方式回购公司A股股份方案的议案》。根据《公司章程》有关规定，公司本次回购方案无须提交股东会审议。
二、回购方案的主要内容
本次回购方案的主要内容如下：
回购方案首次披露日 2026/8/20
回购方案实施期限待董事会审议通过后12个月
方案日期及提议人 2026/8/19，由董事会提议
预计回购金额 100,000万元~200,000万元
回购资金来源自有资金
回购价格上限 81.78元/股
□减少注册资本
√用于员工持股计划或股权激励
回购用途
□用于转换公司可转债
□为维护公司价值及股东权益
回购股份方式集中竞价交易方式
回购股份数量 1,222.79 万股~2,445.59 万股（依照回购价格上限
测算）
回购股份占总股本比例 0.18%~0.37%
回购证券账户名称江苏恒瑞医药股份有限公司回购专用证券账户回购证券账户号码 B882253860
（一）回购股份的目的
基于对公司未来发展前景的信心和基本面的判断，为维护公司和广大投资者的利益，完善公司员工长效激励机制，充分调动员工的积极性，公司计划以自有资
金回购公司A股股份。本次回购的股份将用于A股员工持股计划。
（二）拟回购股份的种类
公司发行的人民币普通股A股。
（三）回购股份的方式
通过上海证券交易所交易系统以集中竞价交易方式回购A股股份。
（四）回购股份的实施期限
1、回购期限为自董事会审议通过回购方案之日起不超过 12 个月。如果触及以下条件，则回购期限提前届满：
（1）如果在回购期限内回购金额达到最高限额，则回购方案实施完毕，即回购期限自该日起提前届满；
（2）如董事会决定终止本回购方案，则回购期限自董事会决议终止本回购方案之日起提前届满。
董事会将在回购期限内根据市场情况择机做出回购决策并予以实施。
2、公司在以下期间不得回购A股股份：
（1）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项发生之日或者在决策过程中至依法披露之日；
（2）中国证券监督管理委员会（以下简称"中国证监会"）及上海证券交易所规定的其他情形。
回购方案实施期间，若公司股票因筹划重大事项连续停牌 10 个交易日以上，回购方案将在股票复牌后顺延实施并及时披露。
（五）回购股份的用途、数量、占公司总股本的比例、资金总额
本次回购的股份计划用于公司 A 股员工持股计划，若公司未能在股份回购实施完成之后36个月内使用完毕已回购的股份，公司将依法对回购的股份予以注销，具体由董事会授权公司管理层依据有关法律法规决定实施方式。公司拟用于回购的资金总额不低于人民币 10 亿元，不超过人民币 20 亿元，具体回购资金总额以回购期满时实际回购的资金为准。如以回购资金总额上限人民币20亿元、回购价格上限 81.78 元/股测算，预计回购股份数量约为 2,445.59 万股，约占公司目前总股本的0.37%。
若公司在回购期内发生资本公积转增股本、派发股票或现金红利、股票拆细、缩股、配股或发行股本权证等事宜，自股价除权除息之日起，相应调整回购股份数
量。具体回购股份的数量以回购期满时实际回购的股份数量为准。
（六）回购股份的价格或价格区间、定价原则
本次回购价格不超过81.78元/股（含），该回购股份价格上限不高于董事会审议通过本次回购方案前30个交易日公司A股股份交易均价的150%。具体回购价格由董事会在回购期间，综合公司二级市场股票价格、公司财务状况和经营状况确定。
若公司在回购期内发生资本公积转增股本、派发股票或现金红利等事宜，自股价除权除息之日起，相应调整回购价格上限。上述回购价格亦需满足有关法律法规及上海证券交易所相关规定对回购价格的相关要求。
（七）回购股份的资金来源
本次用于回购股份的资金来源为公司自有资金。
（八）预计回购后公司股权结构的变动情况
以目前公司总股本为基础，按照本次计划回购资金总额下限人民币10亿元和上限人民币 20 亿元，以及回购价格上限人民币 81.78 元/股测算，若本次回购股份全部用于实施 A 股员工持股计划并全部予以锁定，预计公司股权结构的变动情况如下：
回购后回购后本次回购前
（按回购下限计算）（按回购上限计算）股份类别
股份数量比例股份数量比例股份数量比例
（（股股））（（%））（（股股））（（%））（（股股））（（%））一、有限售条件流通股份 0 0 0 0 0 0二、无限售条件流通股份 6,637,199,874 100 6,637,199,874 100 6,637,199,874 100其中：人民币普通股（A
6,379,002,274 96.11 6,379,002,274 96.11 6,379,002,274 96.11股）
其中：回购专
11,431,250 0.17 23,659,179 0.36 35,887,107 0.54用证券账户
境外上市外资股（H
258,197,600 3.89 258,197,600 3.89 258,197,600 3.89
股）
股份总数 6,637,199,874 100 6,637,199,874 100 6,637,199,874 100
上述测算数据仅供参考，具体回购股份数量及公司股本结构实际变动情况以后续实施情况为准。
（九）本次回购股份对公司日常经营、财务、研发、盈利能力、债务履行能
力、未来发展及维持上市地位等可能产生的影响的分析
As of June 30, 2026 (unaudited), the company's total assets were 70.773 billion yuan, net assets attributable to shareholders of listed companies were 64.466 billion yuan, and current assets were 49.608 billion yuan. The funds for this share repurchase come from the company's own funds. Assuming that the upper limit of 2 billion yuan (inclusive) of the repurchase funds is fully used, based on the financial data on June 30, 2026, the repurchase funds account for a small proportion of the company's total assets, net assets attributable to shareholders of the listed company, and current assets respectively. Based on the company's current operations, finance and future development plans, the company believes that this share repurchase will not have a significant adverse impact on the company's ongoing operations and future development, nor will it have a significant adverse impact on the company's profitability, debt fulfillment ability and research and development capabilities; the implementation of this repurchase plan will not lead to a change in the company's control. After the repurchase, the company's equity distribution meets the conditions of a listed company and will not affect the company's listing status.
The company's share repurchase is used to implement the A-share employee stock ownership plan, which is conducive to improving the company's long-term incentive mechanism for employees, fully mobilizing employees' enthusiasm, enhancing the company's core competitiveness, enhancing the company's overall value, and promoting the company's long-term, healthy and sustainable development.
(10) Whether directors, senior managers, controlling shareholders and actual controllers of listed companies bought and sold shares of the company within 6 months before the board of directors made a resolution to repurchase shares, whether there were any instructions on insider trading and market manipulation alone or jointly with others, and plans for increase or decrease in shareholdings during the repurchase period
After self-examination, the company’s controlling shareholders, actual controllers, directors, and senior managers did not buy or sell the company’s shares in the six months before the board of directors made the resolution to repurchase shares during their term of office, nor did they engage in insider trading or market manipulation alone or jointly with others.
As of the date when the board of directors considers and approves the repurchase plan, the company's directors, senior managers, controlling shareholders, and actual controllers have no plans to increase or decrease their shareholdings during the repurchase period. If they plan to implement a plan to increase or decrease their shareholdings in the future, they will perform their information disclosure obligations in a timely manner in accordance with the requirements of laws, regulations, and normative documents.
(11) Listed companies ask directors, senior managers, controlling shareholders, actual controllers, and shareholders holding more than 5% of the shares whether there are specific plans to reduce their shareholdings in the next three months and the next six months.
The company has separately sent inquiries to directors, senior managers, controlling shareholders, actual controllers, and shareholders holding more than 5% of the shares, and the responses received are as follows: As of the date of the board of directors' approval of the repurchase plan, the company's directors, senior managers, controlling shareholders, actual controllers, and shareholders holding more than 5% of the shares have no plans to reduce their shareholdings in the next three months or the next six months. If the above-mentioned entities plan to implement a share reduction plan in the future, the company will promptly perform its information disclosure obligations in accordance with laws, regulations and normative documents.
(12) Relevant arrangements for cancellation or transfer of shares after repurchase in accordance with the law
The shares repurchased this time will be used for the A-share employee stock ownership plan, and the company will complete the grant or transfer within 36 months after disclosing the results of the repurchase of shares and the announcement of share changes. If the company fails to use up the repurchased shares within the above period, the company will cancel the unused repurchased shares in accordance with the requirements of the Company Law, Securities Law and other laws and regulations. The specific implementation will be carried out in accordance with the relevant laws, regulations and policies.
(13) Relevant arrangements of the company to prevent infringement of the interests of creditors
The shares repurchased this time are intended to be used as a source of shares for the A-share employee stock ownership plan and will not affect the company's normal ongoing operations or cause the company to become insolvent. If the company fails or fails to fully implement the above purposes, the company will cancel the unused repurchased shares in accordance with relevant laws and regulations, and perform legal procedures such as notifying creditors of the cancellation of shares to fully protect the legitimate rights and interests of creditors.
(14) Specific authorization to handle the repurchase of shares
In order to ensure the smooth implementation of the company's repurchase plan, the board of directors authorizes the company's operating management to handle all matters related to this repurchase within the scope of laws and regulations and in accordance with relevant laws, regulations and normative documents, including but not limited to:
To the extent permitted by laws, regulations and normative documents, and based on the specific conditions of the company and the market, formulate and adjust the specific implementation plan for this repurchase, including but not limited to repurchase timing, repurchase price, repurchase quantity and other matters related to this repurchase;
Establish a special securities account for repurchase or other related securities accounts;
Handle relevant approval matters, including but not limited to signing, executing, modifying, and completing all documents related to this repurchase;
Except for matters involving relevant laws, regulations, normative documents and the "Articles of Association" that must be voted on by the board of directors and shareholders' meeting, make corresponding adjustments to matters related to this repurchase based on the opinions of regulatory authorities, changes in policies or changes in market conditions;
Decide to implement or terminate this repurchase plan based on the company's actual situation, stock price performance and other comprehensive circumstances; 6. Handle other matters related to this repurchase.
The above authorization is valid from the date of review and approval by the board of directors to the date when the above matters are completed.
3. Uncertainty risks of repurchase plan
If the company’s stock price continues to exceed the price range disclosed in the repurchase plan during the repurchase period, there may be a risk that the repurchase plan cannot be implemented;
During the implementation of the repurchase plan, the company is affected by factors such as macroeconomic control and temporary operating needs, resulting in the funds required to repurchase the shares not being available in time, resulting in the risk that the repurchase plan cannot be implemented as planned; 3. Due to major changes in the company's production and operation, financial status, external objective conditions, etc., there may be a risk of changing or terminating the repurchase plan in accordance with relevant regulations;
The shares repurchased this time are used for the company's A-share employee stock ownership plan. There may be a risk that the repurchased shares cannot be granted or transferred due to reasons such as the inability to implement the A-share employee stock ownership plan.
公司将在回购期限内根据市场情况择机做出回购决策并予以实施，并根据回购股份事项进展情况及时履行信息披露义务，敬请广大投资者注意投资风险。
四、其他事项说明
（一）回购专用账户开立情况
根据相关规定，公司已在中国证券登记结算有限责任公司上海分公司开立了股份回购专用账户，专用账户情况如下：
持有人情况：江苏恒瑞医药股份有限公司回购专用证券账户
证券账户号码：B882253860
（二）回购期间信息披露
公司将根据相关法律法规和规范性文件的规定，在实施回购期间及时履行信息披露义务。
特此公告。
江苏恒瑞医药股份有限公司董事会
2026年8月26日